What is Ipamorelin? What it does, benefits and what the evidence shows

Ipamorelin is a synthetic five-amino-acid peptide that activates ghrelin receptors to trigger the pituitary gland into releasing the body's own growth hormone. It was first synthesized by researchers at Novo Nordisk in the mid-1990s, has never been approved by FDA or any other drug regulator for any use, and the one published placebo-controlled trial that tested it for a real medical outcome in people — recovery after bowel surgery — did not show a benefit over placebo. This isn't medical advice.

What ipamorelin is and how it works

Ipamorelin (free base) was first synthesized by Novo Nordisk researchers in the mid-1990s and formally described in the scientific literature in 1998 as one of a series of compounds derived by removing the central two amino acids from an earlier growth-hormone-releasing peptide (FDA evaluation memorandum for the Pharmacy Compounding Advisory Committee, 2024, citing Raun et al. 1998). It belongs to a class of compounds called growth hormone secretagogues (GHSs). Rather than supplying growth hormone directly, it works as a "ghrelin mimetic": it activates ghrelin receptors — the same receptors the stomach hormone ghrelin binds — on growth-hormone-releasing neurons in the hypothalamus and on somatotroph cells in the pituitary gland, which in turn triggers the pituitary to release its own stored growth hormone (same FDA memo, citing Hansen et al. 2001 and Raun et al. 1998).

In conscious swine, researchers reported that ipamorelin stimulated growth hormone release without the rise in adrenocorticotropic hormone or cortisol seen with two older growth hormone secretagogues, GHRP-6 and GHRP-2 (Raun et al., Eur J Endocrinol, 1998) — a selectivity FDA's review describes as demonstrated in animal and in vitro work. FDA's review does not identify any published human study confirming that same selectivity profile in people. Because ipamorelin works by prompting the pituitary's own somatotroph cells to secrete growth hormone, it depends on those cells still having some capacity left to respond; FDA's reviewers note it would not be expected to raise growth hormone in someone whose pituitary is absent or severely damaged.

Ipamorelin has never been approved by FDA, the European Medicines Agency, or any other drug regulator for any indication. In grey-market listings it's sold as a research chemical labeled "for research use only," unaffiliated with any approved drug product or its manufacturer.

What people use it for

What the research actually shows

A real human pharmacology study — healthy men, one dose session, no adverse events reported

The only published human pharmacokinetic study of ipamorelin, by Gobburu and colleagues in 1999, was a randomized, placebo-controlled, dose-escalation study in healthy men, delivered by short intravenous infusion across several ascending amounts (cited in FDA's 2024 evaluation memorandum). Ipamorelin showed a short terminal half-life of roughly two hours in the blood, and growth hormone concentrations rose to a sharp peak within about 40 minutes of dosing before falling back to low levels within about six hours at every amount tested. The study's own authors concluded it had "satisfactorily characterized" the relationship between ipamorelin exposure and growth hormone release, and FDA's review notes the study did not report any adverse events. That's real evidence that ipamorelin does what its mechanism predicts — triggers a short-lived pulse of growth hormone in healthy people — and nothing more. It says nothing about whether that pulse produces any downstream benefit.

Postoperative ileus — a real placebo-controlled trial that didn't work

The only published controlled human trial that tested ipamorelin against a real clinical outcome is Beck et al. 2014, a multicenter, double-blind, placebo-controlled phase 2 trial registered on ClinicalTrials.gov (NCT00672074). Researchers enrolled adults undergoing small or large bowel resection by open or laparoscopic surgery and gave them intravenous ipamorelin or placebo starting the day after surgery and continuing for up to a week or until hospital discharge. Of 117 patients enrolled, 114 were included in the safety and efficacy analyses. The primary endpoint — time from the first dose to tolerating a standard solid meal — came in at a median of 25.3 hours in the ipamorelin group versus 32.6 hours with placebo (p = 0.15), which the study reported as not statistically significant. None of the secondary endpoints (time to first bowel movement, length of hospital stay, overall GI recovery) showed a significant difference either, although a subgroup of patients who'd had open surgery showed somewhat faster bowel recovery on ipamorelin. Adverse events were common in both arms, reported in 87.5% of the ipamorelin group and 94.8% of the placebo group, and the authors described ipamorelin as well tolerated. FDA's 2024 review pointed to some imbalances, though: low potassium (12.5% versus 3.4%), insomnia (10.7% versus 5.2%) and high blood sugar at discharge (14.3% versus 8.6%) were more common on ipamorelin, and two ipamorelin-treated patients, both operated on for colon cancer, died of postoperative complications. FDA said it was unclear whether the deaths were related to the drug but that they raise safety concerns. The study's own authors urged caution given the small sample and broad exclusion criteria. According to FDA's review, a later publication (Ishida et al. 2020) summarized the outcome bluntly: development of ipamorelin for this use "was discontinued" because of the disappointing results. A second, larger phase 2 trial for the same use (NCT01280344, 320 patients enrolled between 2011 and 2014) is listed as completed on ClinicalTrials.gov, but we found no published results for it.

Selectivity, GHD, and everything else — animal data or no data

The claim that ipamorelin is a more "selective" growth hormone secretagogue than older compounds rests on animal experiments from the late 1990s and early 2000s, chiefly a 1998 swine study, not on any published human comparison. For growth hormone deficiency (GHD) specifically — the condition every legitimate growth-hormone-releasing compound is eventually judged against — FDA's 2024 review states plainly that it did not identify any data supporting the effectiveness of ipamorelin for GHD in children or adults, and that no professional clinical practice guideline mentions it for that use. For muscle growth, fat loss, recovery, or anti-aging — the claims most commonly attached to ipamorelin in grey-market marketing — we found no controlled human trial testing any of these outcomes. What's actually been shown is a short-lived hormone pulse in healthy volunteers and a negative trial for one specific surgical-recovery use. Everything past that is inference from mechanism, not outcome data.

Side effects and risks

FDA's 2024 safety review flags real signals from the one published clinical trial (covered above), including two deaths among ipamorelin-treated patients with the cause unclear, plus several theoretical concerns, because there's so little human exposure data to draw on. Two theoretical concerns stand out. First, ghrelin receptors are expressed in brain regions that process reward, including the ventral tegmental area, and animal studies of ghrelin itself — the natural hormone ipamorelin mimics — found it increases dopamine release in that region and increases drug-seeking behavior for opioids in rats, while ghrelin receptor blockers reduce those same behaviors. FDA's reviewers describe this as a potential pharmacological class effect that could extend to any ghrelin receptor agonist, ipamorelin included, though it hasn't been studied directly for ipamorelin itself. Second, animal studies of ghrelin and of a ghrelin receptor blocker both showed effects on fertilization and early embryonic development in mice; FDA states it "remains to be determined" whether ipamorelin carries the same risk.

Beyond the theoretical, FDA's adverse-event database search (through September 2023) turned up exactly two non-serious case reports tied to compounded products containing ipamorelin: one involving a compounded nasal spray for sinus headache, where the reporter experienced increased tearing and headache attributed to a product-quality issue; and one involving a combination injectable with sermorelin used off-label for erectile dysfunction, where the patient developed joint pain that didn't fully resolve after stopping. FDA is explicit that adverse-event reports like these can't establish that the product actually caused the problem, and that it can't draw safety conclusions from two reports alone. Separately, FDA's own toxicology reviewers concluded that nonclinical toxicity studies of ipamorelin were "too limited in scope and duration" to properly inform its safety for any clinical use.

On the grey-market side, our data shows a quality pattern worth knowing about that has nothing to do with the biology: ipamorelin vials have run slightly under label on dose more often than most other compounds we track, which is unusual — most peptides in our database skew toward overfill, not underfill.

What the lab tests show

As of September 30, 2026, our database includes 20 ipamorelin vials from 12 vendors, drawn from 18 lab reports dated January 2025 through August 2026. On purity, of 19 vials with a measured result, 17 came in at 99% or higher and 0 under 95%, with a median of 99.77%. As of September 29, 2026, dose accuracy was where this compound stands out from most others in our data — the median measurement ran about 1.6% under label, a slight underfill rather than the overfill pattern common elsewhere. 6 vials landed within ±5% of label, 2 measured more than 20% under label and 1 more than 20% over. Altogether 2 of the 20 tested vials failed our definition (empty, under 95% pure, more than 20% under label, or more than 50% over).

That's a modest sample and a single vendor with a run of vials can move these numbers noticeably — treat this as a snapshot, not a final verdict. Here's how the ranked vendors for ipamorelin look right now; the table shows current verdicts and flags any vendor whose failed-vial rate is above 5%. Ranked isn't automatically good, and for a compound with only 20 total vials tested as of September 29, 2026, this table may be short:

Buying smarter

If you're evaluating a specific vendor's ipamorelin, check their full record on our ipamorelin results page rather than judging off a single report — a vendor needs five or more lab reports before we rank them at all. Given how many of these vials in our data run under label rather than over, a quantity test may be just as informative here as a purity check; how to get a peptide tested walks through ordering independent identity, purity, and quantity testing. Whatever COA a vendor posts is a starting point, not proof: cross-check it against how to read a peptide COA and the red flags in fake peptide COAs before trusting a number you didn't see tested yourself.

Buyers researching ipamorelin often end up comparing it with CJC-1295 or sermorelin, since all three are growth-hormone-releasing peptides sold in the same grey market — worth reading before you decide which one (or combination) you're actually looking at. If your own report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify.

Database figures without a date update automatically from VendorVerify's lab results; dated figures are snapshots. This isn't medical advice; ipamorelin is sold for research use only and has not been evaluated by FDA for safety or effectiveness in humans.